ВИКОРИСТАНА ЛІТЕРАТУРА

1. Tannock, Ian F. "Cancer: Resistance through repopulation." Nature 517.7533 (2015): 152-153.

2. Zhi J., Chen B., Xia G. The reversal effect of magnetic Fe3O4 nanoparticles loaded with cisplatin on SKOV3/DDP ovarian carcinoma cells // International Jornal of nanomedicine. – 2009. – Vol.4. – P.107–114.

3. Lu W., Lin J., Chen J. Expression of p14ARF Overcomes Tumor Resistance to p53 // Cancer Res. – 2002. – Vol.62. – P.1305.

4. Johnston, James B., Paul Daeninck, Linda Verburg, Kristine Lee, Gaynor Williams, Lyonel G. Israels, Michael RA Mowat, and Asher Begleiter. "P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia." Leukemia & lymphoma 26, no. 5-6 (1997): 435-449.

5. Zhang G. Fe(3)O(4)nanoparticles with daunorubicin induce apoptosis through caspase 8–PARP pathway and inhibit K562 leukemia cell–induced tumor growth in vivo// Nanomedicine. – 2011.– Vol.5.– P.595–603.

6. Sakai W., Swisher E., Karlan B. Secondary mutations as a mechanism of cisplatin resistance in BRCA2–mutated cancers // Nature.– 2008. –Vol. 451 – №7182. – Р.16–20.

7. Zhang Z., Wang H., Li M. Novel MDM2 p53–independent functions identified through RNA silencing technologies // Ann N Y Acad Sci. – 2005. –Vol.1058. – P.205 – 214.

8. Tassone P., Tagliaferri P., Perricelli A., et al. BRCA1 expression modulates chemosensitivity of BRCA1–defective HCC1937 human breast cancer cells // Br. J. Cancer – 2003. – Vol.88. - №8. – P.1285–1291.

9. Harbottle A., Daly A.K., Atherton K., Campbell F.C. Role of glutathione S–transferase P1, P–glycoprotein and multidrug resistance–associated protein 1 in acquired doxorubicin resistance // Int. J. Cancer – 2001. – Vol.92. - № 6. – P.777–783.